174 related articles for article (PubMed ID: 12727840)
1. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
[TBL] [Abstract][Full Text] [Related]
2. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
Duan Z; Lamendola DE; Duan Y; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2005 Mar; 55(3):277-85. PubMed ID: 15565326
[TBL] [Abstract][Full Text] [Related]
3. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.
Duan Z; Feller AJ; Penson RT; Chabner BA; Seiden MV
Clin Cancer Res; 1999 Nov; 5(11):3445-53. PubMed ID: 10589757
[TBL] [Abstract][Full Text] [Related]
4. GBP1 overexpression is associated with a paclitaxel resistance phenotype.
Duan Z; Foster R; Brakora KA; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2006 Jan; 57(1):25-33. PubMed ID: 16028104
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
6. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
Kumar A; Soprano DR; Parekh HK
Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
[TBL] [Abstract][Full Text] [Related]
7. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
8. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
9. Non-cytotoxic and sublethal paclitaxel treatment potentiates the sensitivity of cultured ovarian tumor SKOV-3 cells to lysis by lymphokine-activated killer cells.
Law KS; Chen HC; Liao SK
Anticancer Res; 2007; 27(2):841-50. PubMed ID: 17465210
[TBL] [Abstract][Full Text] [Related]
10. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X
Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259
[TBL] [Abstract][Full Text] [Related]
11. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
[TBL] [Abstract][Full Text] [Related]
12. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
13. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
[TBL] [Abstract][Full Text] [Related]
14. [The selection of taxol resistance associated genes in ovarian cancer cell line by mRNA DD].
Cheng G; Tian F; Li Y
Zhonghua Yi Xue Za Zhi; 2000 Jul; 80(7):541-3. PubMed ID: 11798816
[TBL] [Abstract][Full Text] [Related]
15. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells.
Kajiyama H; Shibata K; Terauchi M; Yamashita M; Ino K; Nawa A; Kikkawa F
Int J Oncol; 2007 Aug; 31(2):277-83. PubMed ID: 17611683
[TBL] [Abstract][Full Text] [Related]
16. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
Duan Z; Foster R; Bell DA; Mahoney J; Wolak K; Vaidya A; Hampel C; Lee H; Seiden MV
Clin Cancer Res; 2006 Sep; 12(17):5055-63. PubMed ID: 16951221
[TBL] [Abstract][Full Text] [Related]
17. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
18. Differential gene expression profiles in paclitaxel-induced cell cycle arrest and apoptosis in human breast cancer MCF-7 cells.
Wang J; He FT; Tzang CH; Fong WF; Xiao PG; Han R; Yang MS
Yao Xue Xue Bao; 2005 Dec; 40(12):1099-104. PubMed ID: 16496673
[TBL] [Abstract][Full Text] [Related]
19. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
20. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]